WO2019175722A1
|
|
Process for the preparation of stable and highly pure crystalline form 2 of bilastine
|
WO2018042305A1
|
|
Improved processes for preparation of bilastine using novel intermediates
|
WO2018011676A1
|
|
Novel processes for the preparation of 2-oxy-benzoxazinone derivatives
|
EP3413891A1
|
|
Processes for the preparation of highly pure prucalopride succinate and its intermediates
|
WO2017055935A1
|
|
Amorphous co-precipitates of flibanserin
|
WO2016079757A2
|
|
Novel processes for preparing 5-hydroxymethyl-oxazolidin-2-one derivatives
|
WO2015111076A2
|
|
Improved processes for the preparation of highly pure rivaroxaban crystal modification i
|
WO2016046833A2
|
|
Improved processes for the preparation of agomelatine using novel intermediates
|
WO2015177801A1
|
|
Novel process for the preparation of a lactam-containing compound
|
WO2015132794A1
|
|
Improved processes for the preparation of dabigatran etexilate using novel intermediates
|
WO2015037010A1
|
|
Preparation of vilazodone hydrochloride crystalline form iv
|
WO2014006637A2
|
|
Improved process for preparing benzofuran-2-carboxamide derivatives
|
US2016102064A1
|
|
Processes for the preparation of linezolid using novel intermediates
|
EP2909166A1
|
|
Processes for the preparation of agomelatine using novel intermediates
|
WO2014045292A1
|
|
Improved process for the preparation of linezolid intermediate
|
WO2014016842A1
|
|
Amorphous coprecipitates of rivaroxaban
|
WO2014013498A1
|
|
Amorphous coprecipitates of linezolid
|
WO2013190559A1
|
|
Improved processes for the preparation of linezolid crystalline form iii
|
AU2012378913A1
|
|
Improved process for preparing rivaroxaban using novel intermediates
|
WO2013118130A1
|
|
A process for the preparation of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl) phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophene carboxamide
|